AzTrials
AzTrials

CancerPhase 3NCT03148418

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

A Phase 3 study testing Atezolizumab and Bevacizumab in people with Cancer, run by Hoffmann-La Roche at 170 sites in 32 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at… Read more about this study

Who is it for?
Any age
Conditions the study is for
Cancer
What is being tested?
Atezolizumab and Bevacizumab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
382 participants
Where
170 sitesin 32 countries
Study dates
20 Sep 2017to 30 Nov 2026
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Specific criteria for patients who continue treatment as well as safety and survival follow-up in the extension study (and survival follow up for pattients who roll over from IMpower133):
  • Eligible for continuing or crossing over to atezolizumab-based therapy at the time of the parent-study closure as per the parent study or eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study at the time of the parent-study closure as per the parent study, with no access to commercially available comparator agent
  • First dose of study treatment in the extension study will be received within 7 days of the treatment interruption window allowed by the parent study
  • Continue to benefit from atezolizumab-based study treatment or from the comparator at the time of parent-study closure as assessed by the investigator
  • Negative serum pregnancy test within 7 days prior to start of study treatment in women of childbearing potential
  • Specific criteria for patients from the IMpower133 parent study only who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study:
  • Discontinuation of atezolizumab-based therapy in the IMpower133 parent study and in survival follow- up at the time of IMpower133 parent study closure, or eligible for continuing or crossing over to atezolizumab-based therapy as per the IMpower133 parent protocol and have access to commercially available atezolizumab (Tecentriq) outside this extension study at the time of the IMpower133 parent-study closure

Who cannot join

  • Specific criteria for patients who continue treatment as well as safety and survival follow-up in the extension study:
  • Meet of any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in the extension study
  • Study treatment is commercially marketed in the patient's country for the patient specific disease and is accessible to the patient
  • Time between the last dose of treatment received in parent study and first dose in extension study is longer than the interruption period (± 7 days) allowed in the parent study
  • Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in the extension study
  • Permanent discontinuation of atezolizumab for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study (if applicable)
Show all 12Show fewer
  • Any unresolved or irreversible toxicities during the parent study that required permanent discontinuation of study treatment, in accordance to the parent study or local prescribing information
  • Ongoing SAE(s) that has not resolved to baseline level or Grade less than or equal to (<=) 1 from the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study
  • Any serious uncontrolled concomitant disease that would contraindicate the use of study treatment at the time of the extension study or that would place the participant at high risk for treatment-related complications
  • Concurrent participation in any therapeutic clinical trial (other than the parent study)
  • Specific criteria for patients who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study:
  • Discontinuation of comparator in parent study and in survival follow-up at the time of parent study closure

Trial locations and contacts

170 sites in 32 countries.

170 sites in 32 countries

United States44 sites

  • New York Oncology Hematology, P.C.

    Albany, New York, 12206

  • University Of Colorado

    Aurora, Colorado, 80045

  • Johns Hopkins Univ Med Center

    Baltimore, Maryland, 21231

  • Massachusetts General Hospital.

    Boston, Massachusetts, 02114

  • Beth Israel Medical Center

    Boston, Massachusetts, 02215

  • Dana Farber Cancer Inst.

    Boston, Massachusetts, 02215

  • Northwestern University

    Chicago, Illinois, 60611

  • Rush University Medical Center

    Chicago, Illinois, 60612-3244

  • University Of Chicago Medical Center

    Chicago, Illinois, 60637

  • Cleveland Clinic

    Cleveland, Ohio, 44195

  • Maryland Oncology Hematology, P.A.

    Columbia, Maryland, 21044

  • Texas Oncology - DFW

    Dallas, Texas, 75246

  • Rocky Mountain Cancer Ctr - Denver (Williams)

    Denver, Colorado, 80218

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201

  • Oncology Associates of Oregon, P.C

    Eugene, Oregon, 97401

  • Summit Medical Center

    Florham Park, New Jersey, 07932

  • Florida Cancer Specialists - Fort Myers (Broadway)

    Fort Myers, Florida, 33901

  • Ingalls Memorial Hospital

    Harvey, Illinois, 60426

  • Penn State Hershey Cancer Institute

    Hershey, Pennsylvania, 17033

  • Carolina BioOncology Institute, PLCC

    Huntersville, North Carolina, 28078

  • Comprehensive Cancer Centers of Nevada - Eastern Avenue

    Las Vegas, Nevada, 89169

  • Angeles Clinic & Rsch Inst

    Los Angeles, California, 90025

  • UCLA

    Los Angeles, California, 90095

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital

    Marietta, Georgia, 30060

  • Sarah Cannon Res Inst

    Nashville, Tennessee, 37203

  • Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut, 06510

  • Memorial Sloan-Kettering Cancer Center

    New York, New York, 10065

  • Virginia Oncology Associates

    Norfolk, Virginia, 23502

  • Illinois Cancer Care

    Peoria, Illinois, 61615

  • Allegheny Cancer Center

    Pittsburgh, Pennsylvania, 15212

  • Hematology Oncology Associates of the Treasure Coast

    Port Saint Lucie, Florida, 34952

  • Northwest Cancer Specialists - Portland (N Broadway)

    Portland, Oregon, 97227

  • Blue Ridge Cancer Care

    Roanoke, Virginia, 24014

  • US oncology research at Minnesota Oncology

    Saint Louis Park, Minnesota, 55416

  • Kaiser Permanente - San Diego (Zion Ave)

    San Marcos, California, 92078

  • HonorHealth Research Institute ? Bisgrove

    Scottsdale, Arizona, 85258

  • University of Washington Seattle Cancer Care Alliance

    Seattle, Washington, 98109

  • Washington University School of Medicine

    St Louis, Missouri, 63110

  • Florida Cancer Specialists.

    St. Petersburg, Florida, 33705

  • Northwest Medical Specialties

    Tacoma, Washington, 98405

  • H. Lee Moffitt Cancer Center and Research Inst.

    Tampa, Florida, 33612

  • Tyler Cancer Center

    Tyler, Texas, 75702

  • Georgetown University Medical Center Lombardi Cancer Center

    Washington D.C., District of Columbia, 20057

  • New England Cancer Specialists

    Westbrook, Maine, 04092

Other trials in United States

Spain24 sites

  • Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología

    A Coruña, LA Coruna, 15006

  • Hospital del Mar

    Barcelona, 08003

  • Vall d'Hebron Institute of Oncology (VHIO), Barcelona

    Barcelona, 08035

  • Hospital Clinic de Barcelona. Unidad de Nuevas Terapias

    Barcelona, 08036

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08041

  • Institut Catala d Oncologia Hospital Duran i Reynals

    Barcelona, 08908

  • Hospital Universitari Germans Trias i Pujol

    Barcelona, 08916

  • Hospital San Pedro De Alcantara

    Cáceres, 10003

  • Hospital Universitario Reina Sofia

    Córdoba, Cordoba, 14004

  • Complejo Hospitalario de Jaen

    Jaén, 23007

  • Hospital Universitario Materno Infantil de Gran Canaria

    Las Palmas de Gran Canaria, LAS Palmas, 35016

  • Hospital Lucus Augusti

    Lugo, 27003

  • Hospital General Universitario Gregorio Marañon

    Madrid, 28007

  • Hospital Ramon y Cajal

    Madrid, 28034

  • Hospital Universitario Clínico San Carlos

    Madrid, 28040

  • Hospital Universitario 12 de Octubre

    Madrid, 28041

  • Hospital Universitario La Paz

    Madrid, 28046

  • Hospital de Madrid Norte Sanchinarro- Centro Integral Oncologico Clara Campal

    Madrid, 28050

  • Hospital Regional Universitario Carlos Haya

    Málaga, 29010

  • Hospital Son Llatzer

    Palma de Mallorca, Balearic Islands, 07198

  • Clinica Universitaria de Navarra

    Pamplona, Navarre, 31008

  • Hospital Universitario Virgen del Rocio

    Seville, 41013

  • Hospital General Universitario de Valencia

    Valencia, 46014

  • Hospital NisA 9 de Octubre

    Valencia, 46015

Other trials in Spain

Italy18 sites

  • Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato

    Arezzo, Tuscany, 52100

  • Policlinico Vittorio Emanuele

    Catania, Sicily, 95123

  • IRCCS AOU San Martino - IST

    Genoa, Liguria, 16132

  • ASL 3 Genovese

    Genoa, Liguria, 16149

  • Irccs Istituto Nazionale Dei Tumori (Int)

    Milan, Lombardy, 20133

  • Irccs Istituto Europeo Di Oncologia (IEO)

    Milan, Lombardy, 20141

  • A.O. Universitaria Policlinico Di Modena

    Modena, Emilia-Romagna, 41100

  • Asst Di Monza

    Monza, Lombardy, 20900

  • Azienda Osp Uni Seconda Università Degli Studi Di Napoli

    Naples, Campania, 80131

  • Azienda Ospedaliera A. Cardarelli

    Naples, Campania, 80131

  • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale

    Naples, Campania, 80131

  • A.O.U. Maggiore della Carità

    Novara, Piedmont, 28100

  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga

    Orbassano, Piedmont, 10043

  • IOV - Istituto Oncologico Veneto - IRCCS

    Padova, Veneto, 35128

  • Ospedale Santa Maria Della

    Perugia, Umbria, 06129

  • A.O. Universitaria Pisana-Ospedale Cisanello

    Pisa, Tuscany, 56124

  • Università Cattolica Del S Cuore

    Rome, Lazio, 00168

  • Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica

    Siena, Tuscany, 53100

Other trials in Italy

France14 sites

  • Hopital Jean Minjoz

    Besançon, 25030

  • Chu Grenoble - Hopital Albert Michallon

    Grenoble, 38043

  • Centre Leon Berard

    Lyon, 69373

  • Hopital Nord

    Marseille, 13915

  • Centre René Gauducheau - cancer Nantes - Atlantique

    Nantes, 44805

  • Centre Antoine Lacassagne, Centre de Lutte Contre le Cancer (CLCC) de Nice

    Nice, 06189

  • Hopital Saint Louis

    Paris, 75475

  • GH Paris Saint Joseph

    Paris, 75674

  • Hopital Tenon

    Paris, 75970

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495

  • CH de Saint Quentin

    Saint-Quentin, 2100

  • Centre Medico-Chirurgical Foch

    Suresnes, 92151

  • CHU de Toulouse - Hôpital Larrey

    Toulouse, 31059

  • Institut Gustave Roussy

    Villejuif, 94805

Other trials in France

United Kingdom9 sites

  • Barts & London School of Med

    London, EC1A 7BE

  • Royal Free Hospital

    London, NW3 2QG

  • St George's Hospital

    London, SW17 0QT

  • Royal Marsden Hospital - London

    London, SW3 6JJ

  • Charing Cross Hospital

    London, W6 8RF

  • Christie Hospital NHS Trust

    Manchester, M20 4BX

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    Metropolitan Borough of Wirral, L63 4JY

  • Nottingham City Hospital

    Nottingham, NG5 1PB

  • Royal Marsden Hospital - Surrey

    Surrey, SM2 5PT

Other trials in United Kingdom

Japan8 sites

  • Shikoku Cancer Center

    Ehime, 791-0280

  • Sendai Kousei Hospital

    Miyagi, 981-0914

  • Niigata Cancer Center Hospital

    Niigata, 951-8566

  • Iwate Medical University Hospital

    Numakunai, 028-3695

  • Okayama University Hospital

    Okayama, 700-8558

  • Toranomon Hospital

    Tokyo, 105-8470

  • The Cancer Institute Hospital of JFCR, Respiratory Medicine

    Tokyo, 135-8550

  • Wakayama Medical University Hospital

    Wakayama, 641-8510

Other trials in Japan

Canada7 sites

  • Royal Victoria Hospital

    Barrie, Ontario, L4M 6M2

  • William Osler Health Centre

    Brampton, Ontario, L6R 3J7

  • Cite de La Sante de Laval

    Laval, Quebec, H7M 3L9

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2

  • Lakeridge Health Corporation-Oshawa

    Oshawa, Ontario, L1G 2B9

  • Sunnybrook Odette Cancer Centre

    Toronto, Ontario, M4N 3M5

  • Princess Margaret Cancer Center

    Toronto, Ontario, M5G 1Z5

Other trials in Canada

South Korea4 sites

  • National Cancer Center

    Gyeonggi-do, 10408

  • Seoul National University Bundang Hospital

    Gyeonggi-do, 13620

  • Chonnam National University Hwasun Hospital

    Jeollanam-do, 58128

  • Samsung Medical Center

    Seoul, 06351

Other trials in South Korea

Brazil3 sites

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, 14784-400

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, 01246-000

  • Fundacao Antonio Prudente

    São Paulo, São Paulo, 01509-900

Other trials in Brazil

Poland3 sites

  • Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii

    Gdansk, 80-952

  • Oddzia? Onkologii Klinicznej i Chemioterapii Szpitala ELBL?SKA

    Warsaw, 01-748

  • Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad

    Warsaw, 02-781

Other trials in Poland

Taiwan3 sites

  • Changhua Christian Hospital

    Changhua, 500

  • China Medical University Hospital

    Taichung, 40447

  • National Taiwan Uni Hospital

    Taipei, 100

Other trials in Taiwan

Thailand3 sites

  • Chulalongkorn Hospital

    Bangkok, 10330

  • Ramathibodi Hospital

    Bangkok, 10400

  • Faculty of Med. Siriraj Hosp.

    Bangkok, 10700

Other trials in Thailand

Turkey (Türkiye)3 sites

  • Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi

    Edirne, 22030

  • Istanbul Uni Cerrahpasa Medical Faculty Hospital

    Istanbul, 34300

  • Hacettepe Uni Medical Faculty Hospital

    S?hhiye, Ankara, 06100

Other trials in Turkey (Türkiye)

Australia2 sites

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, 2050

  • Princess AleXandra Hospital

    Woolloongabba, Queensland, 4102

Other trials in Australia

Austria2 sites

  • Klinik Penzing

    Vienna, 1140

  • Krankenhaus Nord - Klinik Floridsdorf

    Vienna, 1210

Other trials in Austria

Belgium2 sites

  • AZ Glorieux- vzw Werken Glorieux

    Ronse, 9600

  • ZAS Sint Augustinus Wilrijk

    Wilrijk, 2610

Other trials in Belgium

Czechia2 sites

  • Masarykuv onkologicky ustav

    Brno, 656 53

  • Thomayerova nemocnice

    Praha 4 - Krc, 140 59

Other trials in Czechia

Hungary2 sites

  • Semmelweis Egyetem X

    Budapest, 1083

  • Református Pulmonológiai Centrum

    Törökbálint, 2045

Other trials in Hungary

Portugal2 sites

  • Hospital de Santa Maria

    Lisbon, 1649-035

  • Centro Hospitalar do Porto ? Hospital de Santo António

    Porto, 4099-001

Other trials in Portugal

Romania2 sites

  • Institut Oncologic Ion Chiricuta

    Cluj-Napoca, 400015

  • ONCOMED - Medical Centre

    Timișoara, 300239

Other trials in Romania

Serbia2 sites

  • Clinic for Pulmonology, Clinical Center of Serbia

    Belgrade, 11000

  • University Hospital Medical Center Bezanijska kosa

    Belgrade, 11080

Other trials in Serbia

Argentina1 site

  • Fundación CENIT para la Investigación en Neurociencias

    Buenos Aires, C1125ABD

Other trials in Argentina

Bulgaria1 site

  • Multiprofile Hospital for Active Treatment Serdika EOOD

    Sofia, 1303

Other trials in Bulgaria

Chile1 site

  • Bradford Hill Centro de Investigaciones Clinicas

    Recoleta, 8420383

Other trials in Chile

Germany1 site

  • Klinikum d.Universität München Campus Großhadern

    München, 81377

Other trials in Germany

Israel1 site

  • Belinson Medical Center

    Petah Tikva, 4922297

Other trials in Israel

Netherlands1 site

  • NKI/AvL

    Amsterdam, 1066 CX

Other trials in Netherlands

New Zealand1 site

  • Auckland city hospital

    Auckland, 1023

Other trials in New Zealand

Russia1 site

  • Moscow City Oncology Hospital #62

    Moscow, Moscow Oblast, 121205

Other trials in Russia

Slovenia1 site

  • Institute of Oncology Ljubljana

    Ljubljana, 1000

Other trials in Slovenia

Switzerland1 site

  • CHUV

    Lausanne, 1011

Other trials in Switzerland

Ukraine1 site

  • Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU

    Dnipropetrovsk, 49102

Other trials in Ukraine

About this study

Official title: An Open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study

This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure and do not have access to the study treatment locally are eligible for continued treatment in the extension study. Dosing regimen for a given participant and indication will be the same or equivalent to the respective parent study protocol. Study treatment in the extension study can continue until disease progression or beyond if the patient continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; patient non-compliance; or study termination by the Sponsor, whichever occurs first.

Conditions
Cancer
Medical subject headings
Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AtezolizumabDrug

    Also called RO5541267, Tecentriq

    Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).

  • BevacizumabDrug

    Also called Avastin

    Bevacizumab will be administered as directed per the parent study.

Study groups in NCT03148418
Study groupRoleWhat they receive
Atezolizumab MonotherapyExperimentalParticipants will continue to receive atezolizumab monotherapy in a Genentech or Roche-sponsored study (the parent study) in accordance with local prescribing information till the participant continues to derive clinical benefit or until death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first.
Receives: Drug: Atezolizumab
Combined Agents with AtezolizumabExperimentalParticipants will receive treatment of atezolizumab with combined agent(s) as directed per the parent study. Participants will receive agent(s) in combination with atezolizumab at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
Receives: Drug: Atezolizumab; Drug: Bevacizumab
Comparator TreatmentActive comparatorParticipants will receive comparator treatment administration as directed per the parent study. Participants will receive comparator treatment at the same dose and schedule, and with the same administration guidelines that were in effect at the time of participant discontinuation from the parent study.
Receives: Drug: Bevacizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)

    Measured: Day 1 up to maximum 10 years

Secondary outcomes (3)

  1. Percentage of Participants With Serious Adverse Events (SAEs) by Severity Determined According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

    Measured: Day 1 up to 90 days after last dose of study treatment (last dose=till clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)

  2. Percentage of Participants With Adverse Events of Special Interest by Severity Determined According to NCI CTCAE Version 4.0

    Measured: Day 1 up to 90 days after last dose of study treatment (last dose=till clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)

  3. Time from Randomization or Treatment Initiation to Death due to any Cause for IMpower133 Participants Only

    Measured: Day 1 (as indicated in parent study protocol) until death due to any cause (up to maximum 10 years or until the sponsor stop)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 May 2017
  2. Study start20 Sep 2017
  3. Primary completion30 Nov 2026 (estimated)
  4. Study completion30 Nov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
382 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03148418
Sponsor's protocol ID
BO39633
Other IDs
2016-005189-75, 2016
Status last verified
Oct 2026
First submitted
9 May 2017
Last updated
8 Oct 2026
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing

Publications

  • Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, de Castro G Jr, Havel L, Bernabe Caro R, Losonczy G, Lee JS, Kowalski DM, Andric Z, Califano R, Veatch A, Gerstner G, Batus M, Morris S, Kaul M, Cuchelkar V, Li H, Danner BJ, Nabet BY, Liu SV. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study. Lung Cancer. 2024 Oct;196:107924. doi: 10.1016/j.lungcan.2024.107924. Epub 2024 Aug 10.

    PubMed 39306923

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Atezolizumab and Bevacizumab in people with Cancer, run by Hoffmann-La Roche at 170 sites in 32 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 170 sites in United States, Spain, Italy, France, United Kingdom and 27 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s) (time frame: Day 1 up to maximum 10 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03148418, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in